Navigation Links
InfraReDx's New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010

BURLINGTON, Mass., Sept. 17 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that its new LipiScan™ IVUS Coronary Imaging System will be highlighted during the annual Transcatheter Cardiovascular Therapeutics meeting (TCT 2010). The novel device, which was recently cleared by the U.S. Food and Drug Administration (FDA), will be featured in scientific and clinical symposia, live case broadcasts, product demonstrations and poster abstract sessions. TCT 2010 is being held September 21-25, 2010 at the Walter E. Washington Convention Center ("the convention center") in Washington, D.C. TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and showcasing the latest advances in techniques, therapies and clinical research.

The Company expects to conduct a broad commercial launch of the system within the U.S. by year-end 2010, and anticipates regulatory approval and launch in Europe during 2011.

The LipiScan IVUS system utilizes a novel multimodality imaging catheter; the first ever to combine the complementary technologies of near-infrared (NIR) spectroscopy and intravascular ultrasound (IVUS). This combination enables interventional cardiologists to rapidly determine both the structure of plaque (via IVUS) along with its chemical composition (via NIR spectroscopy). NIR spectroscopy is the only technology cleared by the FDA for the specific task of detection of lipid-core coronary plaques (LCP). Such plaques can adversely impact the safety of stenting and are associated with heart attacks that occur in those who have received stents and in the general population.

Dr. James Muller, founder and chief executive officer of InfraReDx, Inc. noted that the "LipiScan IVUS system is the culmination of a major effort to develop a single catheter that utilizes both light and sound to characterize coronary plaques. The novel near-infrared spectroscopic feature is an excellent means to identify lipid core plaque while the traditional ultrasound provides a picture of the plaque that is useful for stenting decisions."  

Dr. Muller stated that "this new multimodality imaging system will provide the interventional cardiologist with additional information about the extent of atherosclerosis within the coronary artery that will help assess the level of risk of stenting procedures. We are pleased to present this breakthrough technology at TCT, the annual meeting for discussion of major advances in interventional cardiology."  

The LipiScan IVUS system will be featured in many sessions at TCT 2010.

I.  Hands-on Product Education and TrainingInfraReDx will host education, hands-on training and live demonstrations of the company's LipiScan IVUS system in the Exhibit Hall at the InfraReDx booth #1800 on Thursday (9:00 a.m. to 5:00 p.m.), Friday (9:00 a.m. to 5:00 p.m.) and Saturday (9:00 a.m. to 2:00 p.m.).  InfraReDx will also participate in the Nurse Tech Symposium held in conjunction with TCT on Tuesday, September 21.  

II. Breakfast SymposiumInfraReDx will host a satellite symposium titled "Novel Multimodality Intracoronary Imaging to Improve Decision-Making, Stenting Safety and Prediction of Outcomes." This hour-long breakfast panel event will begin Thursday, September 23 at 7:00 a.m. in Room 144B of the convention center.  

The breakfast symposium will be chaired by James A. Goldstein, M.D., of William Beaumont Hospital in Royal Oak, Mich. A panel of renowned interventional cardiologists will present their perspectives on topics such as: the importance of identifying plaque composition, the clinical applicability of detecting vulnerable plaque, multimodality imaging technologies, determination of optimal stent length, and the detection and management of lesions at risk for distant embolization. Instructive clinical cases utilizing the LipiScan IVUS coronary imaging system to guide PCI will be presented and discussed.  

The breakfast panel faculty includes: Emmanouil S. Brilakis, M.D., Ph.D.; Simon Dixon, M.D., Ph.D.; David G. Rizik, M.D.; Patrick W. Serruys, M.D., Ph.D. and Gregg W. Stone, M.D. A webcast of this symposium will be available on the InfraReDx website after the close of TCT 2010.

III. "Live Case" DemonstrationsAt least two live case demonstrations of the LipiScan IVUS system are scheduled to be broadcast to the Main Arena of the convention center on Thursday, September 23 and Friday, September 24 (see the TCT 2010 onsite schedule for specific times). The operators for these real-time PCI procedures include:

  • Giora Wiesz, M.D. and Dr. Jeffrey W. Moses, M.D., from the New York-Presbyterian Hospital at Columbia University Medical Center in New York.
  • John L. Petersen, M.D., Mark Reisman, M.D. and Amish J. Desai, M.D. from the Swedish Medical Center in Seattle.

  • Demonstrations of the LipiScan IVUS system can also be viewed in the Exhibit Hall area, at the InfraReDx exhibit booth #1800.

    IV. Scientific SymposiaThe LipiScan system will be discussed in multiple sessions of the scientific program titled "Vulnerable Plaque: Emerging Directions for Diagnosis and Treatment" which takes place on Tuesday, September 21, 8:00 a.m. to 6:00 p.m., in Room 204ABC at the convention center. Highlights of this program include:

  • A discussion by Evelyn S. Regar, M.D., Ph.D., of the Erasmus Medical Center in Rotterdam, Amsterdam, entitled "A Combined IVUS-NIR Spectroscopy Catheter: Development and Clinical Cases," during the "Invasive Imaging" session (V).
  • A presentation by Emmanouil S. Brilakis, M.D., Ph.D., of the Southwestern Medical Center in Dallas, entitled "Case Studies with NIR Spectroscopy," during the "Case Studies in Vulnerable Plaque" session (VI).
  • A presentation by Gregg W. Stone, M.D., of the New York-Presbyterian Hospital at Columbia University Medical Center in New York, entitled "Rationale and Design of the VERDICT and CANARY Studies," during the "Clinical Studies" session (VI). CANARY (Coronary Assessment by Near-Infrared of Atherosclerotic Rupture-prone Yellow) refers to a trial that InfraReDx plans to begin before year-end 2010 to test the hypothesis that LipiScan NIR-guided use of a distal protection device can prevent peri-procedural myocardial infarction (MI) caused by LCPs in patients undergoing PCI.

  • V. Concurrent SessionsThe LipiScan system will be a subject of discussion during a program titled "Next Generation Intravascular Imaging: OCT and NIR," scheduled for Friday, September 24, 2:00 p.m. to 6:00 p.m., in Room 151AB at the convention center. Highlights of this program include:

  • A lecture by Dr. James E. Muller, founder and CEO of InfraReDx. Dr. Muller will present "Making Sense of Near-Infrared Spectroscopy: What Does it Detect and How?" during the "Technology Update" session (I).
  • A lecture by Brijeshwar Maini. M.D., of Pinnacle Health and Vascular Institute in Harrisburg. Dr. Maini will present "Use of NIR Spectroscopy to Risk-Stratify and Guide PCI Procedure" during the "Guiding Percutaneous Coronary Interventions" session (III).
  • Three case presentations during the "OCT and NIR Case Presentations" session (IV): "NIR Spectroscopy and Distal Embolization"; "NIR Spectroscopy and Stent Thrombosis"; and "Novel Insight from NIR Spectroscopy." Presenters include: James A Goldstein, M.D., of William Beaumont Hospital in Royal Oak, Mich., David G. Rizik, M.D., of the Scottsdale Heart Group and Emmanouil S. Brilakis, M.D., Ph.D., of the Southwestern Medical Center in Dallas.

  • VI. Poster Abstract SessionsPoster abstracts will be on view on Wednesday, September 22, 1:30 p.m. to 3:30 p.m., on the Lower Level of the convention center. On display will be two posters featuring NIR spectroscopy using the LipiScan imaging system, both of which have been accepted for publication in the Journal of American Cardiology (JACC).

  • Brugaletta S, et al. "Correlation Between Near-Infrared Spectroscopy and Intravascular Ultrasound with Virtual Histology in the Evaluation of Coronary Atherosclerosis: A Single Center Experience." (Abstract poster TCT-350)
  • Madder RD, et al. "Frequency of Lipid-Core Plaque in Culprit and Non-Culprit Lesions by Intracoronary Near-Infrared spectroscopy." (Abstract poster TCT-355)

  • The LipiScan system will also be highlighted on the final day of the meeting, during the Cardiovascular Imaging segment of the program titled "Top TCT 2010 Lessons and A Lens to the Future!" This wrap-up session takes place on Saturday, September 25, 3:00 p.m. to 5:00 p.m.

    About the LipiScan™ IVUS Coronary Imaging SystemThe LipiScan IVUS Coronary Imaging System is the world's only intravascular imaging system that combines co-registered grayscale intravascular ultrasound (IVUS) together with InfraReDx's proprietary near infrared (NIR) lipid core plaque (LCP) detection technology. The LipiScan IVUS system delivers all the benefits of IVUS plus the lipid core plaque detection power of NIR spectroscopy to help physicians optimize their stenting strategy. The system was designed by cardiologists for cardiologists and provides an unparalleled "one-stop" visual determination of critical coronary health features to assist in the care of coronary patients, including the identification of lipid-core plaques, degree of stenosis, reference vessel diameter, and plaque burden. This information also aids in facilitating proper stent sizing and placement, and in verifying full stent expansion and apposition and may also help guide post-intervention medical therapy. The innovative design enables cardiologists to generate and display the combined Chemogram™/IVUS analysis immediately upon completion of the single catheter pullback.

    Coronary Stenting StatisticsEach year, more than 2 million individuals worldwide undergo coronary stenting. While clinical results of stenting procedures have steadily improved, approximately 30% of individuals undergoing stenting experience a significant adverse event such as peri-stenting myocardial infarction, post-procedure complications from the stented site, or new coronary events at non-stented sites. In most cases, stenting is guided primarily by X-ray angiography, which does not reveal the health of the vessel wall. Increasingly, physicians are recognizing the limitations of relying on angiography alone and are turning to advanced imaging solution systems to optimize stenting strategy.

    About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the vulnerable intracoronary lipid core plaque (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit  Contacts:Susan HeinsPure Communications, Inc.864-286-9597sjheins@purecommunicationsinc.comGrant FrazierVice President of MarketingInfraReDx,

    SOURCE InfraReDx, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
    2. Reportlinker Adds All Change in the Coronary Stent Market
    3. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
    4. Concert Medical Launches Conductor™ Family of Interventional Coronary Guidewires
    5. Global Acute Coronary Syndrome Industry
    6. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
    7. First Coronary Stent on Drug Eluting Balloon Implanted
    8. Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment
    9. LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States
    10. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
    11. Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
    Post Your Comments:
    (Date:10/9/2015)... 9, 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), a leading ... and iForce Nutrition ("iForce"), one of the fastest-growing Sports ... , today announced that they have entered ... agreed to acquire iForce. The transaction will enhance ... distribution through iForce,s strong distribution network. ...
    (Date:10/9/2015)... 2015 Adheron Therapeutics, a privately held ... , United States , ... acquired by Roche.  Adheron Therapeutics has developed a ... a cell surface protein called Cadherin-11 in order ... inflammatory and autoimmune diseases such as rheumatoid arthritis ...
    (Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
    Breaking Medicine Technology:
    ... (Nasdaq: INSM ), a biopharmaceutical company, announced ... Agency (EMA) has issued a positive opinion on the ... for inhalation), Insmed,s Phase 3-ready compound for cystic fibrosis ... infections.  The PIP covers children from birth to 18 ...
    ... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ... announced today it submitted the application to commence clinical ... China,s State Food and Drug Administration (SFDA) on March ... research program in 2008. The vaccine targets infants under ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... October 10, 2015 , ... The sixth annual cost ... the growth of cybercrime costs for US companies. The New York Times broke down ... With averages showing increases hovering around 20% among the companies surveyed, it only proves ...
    (Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser ... It works by reading various classics and inspiring stories and as words drop down ... , The animations are extremely aesthetic and can be interacted with, making it a ...
    (Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
    (Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
    Breaking Medicine News(10 mins):
    ... flu outbreak in February in India, the poultry market saw a ... the government assured the people that all the necessary measures are ... the avian flu the sales of chicken and other birds saw ... deaths due to bird flu the sales dips drastically. Every time ...
    ... of cognitive behavior therapy (CBT) in overcoming depression can ... the University of Pittsburgh School of Medicine. In a ... Journal of Psychiatry, the official journal of the American ... the response to therapy could be a valuable tool ...
    ... who suffer from severe urinary infection are more likely ... had found a link between acute infections and heart ... infections and clotting in large veins, reported the online ... at the London School of Hygiene and Tropical Medicine ...
    ... new genes found with breast tumors can predict the outcomes ... the report appearing in he April 1 issue of Clinical ... women at risk for an early relapse of breast cancer. ... discovered as a potential marker of relapse in hormone-receptor positive ...
    ... from Sheffield University most women still believe one-night stands ... revealed that women of all ages believe that sex ... ,The women community despite achieving liberation still feels ... of desperation or drunkenness. The research which was followed ...
    ... are still left confused despite making in-depth analysis in ... psychiatric problem that affects the children. ... which is beyond the scientists' control, between 30 percent ... co-existing conditions, so-called comorbidities that make diagnosis and treatment ...
    Cached Medicine News:
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: